PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Belinostat

Drugs in development · updated 30 October 2026

Belinostat: clinical trials and development status

Other names and codes: Beleodaq

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Belinostat is in 8 active clinical trials (recruiting or ongoing, phases I–III) for 14 diseases. The most advanced phase is III.

8Active trials
IIIMost advanced phase
14Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Belinostat and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
T-cell lymphomaIII3NCT06561048
Anaplastic large-cell lymphomaIII2NCT06561048
Peripheral T-cell lymphomaIII2NCT06072131
Immunoblastic lymphadenopathyIII1NCT06561048
Eye neoplasmII1NCT05170334
Neuroendocrine carcinomaII1NCT06406465
Neuroendocrine tumorII1NCT06406465
Uveal melanomaII1NCT05170334
B-cell lymphomaI1NCT05627245
Cutaneous T cell lymphomaI1NCT05627245
Enteropathy-associated T-cell lymphomaI1NCT07691450
Follicular lymphomaI1NCT05627245
Non-Hodgkin lymphomaI1NCT05627245
Subcutaneous T-cell lymphomaI1NCT07691450

Everything on Belinostat

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch